Skip to main content

Table 2 Survival data for the patient group (n = 31)

From: The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer

Progression-free survival (PFS)
 Progressions [n (%)] 14 (45.2)
 3-year PFS (%) 61.3
 Range (months) 6.2–47.8
Overall survival (OS)
 Deaths [n (%)] 9 (29.0)
 3-year OS (%) 79.8
 Range (months) 14.9–52.9
Median follow-up (months) 39.7